Cargando…

Pharmacotherapy for mood and anxiety disorders in older people with intellectual disability in comparison with the general population

BACKGROUND: People with intellectual disability (ID) have high prevalence of psychiatric disorders, but even higher rates of prescription of psychotropic drugs. METHODS: Using Swedish national registers, we identified a group of older people with ID and diagnosis of mood disorders (ICD-10 codes F32-...

Descripción completa

Detalles Bibliográficos
Autores principales: Axmon, Anna, El Mrayyan, Nadia, Eberhard, Jonas, Ahlström, Gerd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676521/
https://www.ncbi.nlm.nih.gov/pubmed/31370823
http://dx.doi.org/10.1186/s12888-019-2191-7
_version_ 1783440778151854080
author Axmon, Anna
El Mrayyan, Nadia
Eberhard, Jonas
Ahlström, Gerd
author_facet Axmon, Anna
El Mrayyan, Nadia
Eberhard, Jonas
Ahlström, Gerd
author_sort Axmon, Anna
collection PubMed
description BACKGROUND: People with intellectual disability (ID) have high prevalence of psychiatric disorders, but even higher rates of prescription of psychotropic drugs. METHODS: Using Swedish national registers, we identified a group of older people with ID and diagnosis of mood disorders (ICD-10 codes F32-F39) and/or anxiety (ICD-10 code F4) during 2006–2012 (n = 587) and a referent group of people from the general population with the same diagnoses during the same time period (n = 434). For both groups, we collected information on prescription of anxiolytics, hypnotics and sedatives, antidepressants, and GABA-agonists. RESULTS: Among those with a diagnosis of anxiety, people with ID were more likely than those in the general population to be prescribed anxiolytics (Relative Risk 1.32 [95% Confidence Interval 1.19–1.46]) and GABA-agonists (1.10 [1.08–1.31]). Moreover, among those with anxiety but without mood disorders, ID was associated with increased prescription of antidepressants (1.20 [1.03–1.39]). Within the ID cohort, behaviour impairment and MSP (i.e. moderate, severe, or profound) ID was associated with increased prescription of anxiolytics, both among those with anxiety (1.15 [1.03–1.30] for behaviour impairment and 1.23 [1.10–1.38] for MSP ID) and among those with mood disorders (1.14 [0.97–1.35] for behaviour impairment and 1.26 [1.04–1.52] for MSP ID). Moreover, MSP ID was associated with increased prescription of GABA-agonists among those with anxiety (1.23 [1.10–1.38]). CONCLUSIONS: The excess prescription of anxiolytics but not antidepressants may suggest shortages in the psychiatric health care of older people with intellectual disability and mood and anxiety disorders.
format Online
Article
Text
id pubmed-6676521
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66765212019-08-06 Pharmacotherapy for mood and anxiety disorders in older people with intellectual disability in comparison with the general population Axmon, Anna El Mrayyan, Nadia Eberhard, Jonas Ahlström, Gerd BMC Psychiatry Research Article BACKGROUND: People with intellectual disability (ID) have high prevalence of psychiatric disorders, but even higher rates of prescription of psychotropic drugs. METHODS: Using Swedish national registers, we identified a group of older people with ID and diagnosis of mood disorders (ICD-10 codes F32-F39) and/or anxiety (ICD-10 code F4) during 2006–2012 (n = 587) and a referent group of people from the general population with the same diagnoses during the same time period (n = 434). For both groups, we collected information on prescription of anxiolytics, hypnotics and sedatives, antidepressants, and GABA-agonists. RESULTS: Among those with a diagnosis of anxiety, people with ID were more likely than those in the general population to be prescribed anxiolytics (Relative Risk 1.32 [95% Confidence Interval 1.19–1.46]) and GABA-agonists (1.10 [1.08–1.31]). Moreover, among those with anxiety but without mood disorders, ID was associated with increased prescription of antidepressants (1.20 [1.03–1.39]). Within the ID cohort, behaviour impairment and MSP (i.e. moderate, severe, or profound) ID was associated with increased prescription of anxiolytics, both among those with anxiety (1.15 [1.03–1.30] for behaviour impairment and 1.23 [1.10–1.38] for MSP ID) and among those with mood disorders (1.14 [0.97–1.35] for behaviour impairment and 1.26 [1.04–1.52] for MSP ID). Moreover, MSP ID was associated with increased prescription of GABA-agonists among those with anxiety (1.23 [1.10–1.38]). CONCLUSIONS: The excess prescription of anxiolytics but not antidepressants may suggest shortages in the psychiatric health care of older people with intellectual disability and mood and anxiety disorders. BioMed Central 2019-08-01 /pmc/articles/PMC6676521/ /pubmed/31370823 http://dx.doi.org/10.1186/s12888-019-2191-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Axmon, Anna
El Mrayyan, Nadia
Eberhard, Jonas
Ahlström, Gerd
Pharmacotherapy for mood and anxiety disorders in older people with intellectual disability in comparison with the general population
title Pharmacotherapy for mood and anxiety disorders in older people with intellectual disability in comparison with the general population
title_full Pharmacotherapy for mood and anxiety disorders in older people with intellectual disability in comparison with the general population
title_fullStr Pharmacotherapy for mood and anxiety disorders in older people with intellectual disability in comparison with the general population
title_full_unstemmed Pharmacotherapy for mood and anxiety disorders in older people with intellectual disability in comparison with the general population
title_short Pharmacotherapy for mood and anxiety disorders in older people with intellectual disability in comparison with the general population
title_sort pharmacotherapy for mood and anxiety disorders in older people with intellectual disability in comparison with the general population
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676521/
https://www.ncbi.nlm.nih.gov/pubmed/31370823
http://dx.doi.org/10.1186/s12888-019-2191-7
work_keys_str_mv AT axmonanna pharmacotherapyformoodandanxietydisordersinolderpeoplewithintellectualdisabilityincomparisonwiththegeneralpopulation
AT elmrayyannadia pharmacotherapyformoodandanxietydisordersinolderpeoplewithintellectualdisabilityincomparisonwiththegeneralpopulation
AT eberhardjonas pharmacotherapyformoodandanxietydisordersinolderpeoplewithintellectualdisabilityincomparisonwiththegeneralpopulation
AT ahlstromgerd pharmacotherapyformoodandanxietydisordersinolderpeoplewithintellectualdisabilityincomparisonwiththegeneralpopulation